– Innovative Fertility Treatment Designed to Improve Egg Health, a significant component in In vitro fertilization treatments Success –
CAMBRIDGE, Mass.—(BUSINESS WIRE)—May 7, 2015—OvaScienceSM (NASDAQ: OVAS), a worldwide fertility company centered on the invention, development and commercialization of recent treatments, announced today that among the first patients who received the AUGMENTSM treatment delivered a proper choosing in Toronto, Ontario, Canada.
“Before my spouse and i discovered the AUGMENT treatment, we battled with infertility because of my egg quality and felt somewhat frustrated,” stated mom. “Now we’re positive our experience can have couples, especially individuals who are suffering from poor egg health, they have a brand new option to obtain their own biological child.”
Egg health is really a main factor in female fertility. Even though many factors lead to egg health, getting sufficient stamina-producing mitochondria within the egg is important for healthy fertilization and embryo development. The AUGMENT treatment is made to improve the healthiness of a woman’s existing eggs, and boost the In vitro fertilization treatments procedure. The AUGMENT treatment uses the power-producing mitochondria from the woman’s own egg precursor (EggPCSM) cells – immature egg cells based in the protective lining of her ovaries – to supplement the present mitochondria in her own eggs. The AUGMENT treatment methods are unavailable within the U . s . States.
“You anticipate seeing compromised egg health as women age, however, many more youthful women also provide poor egg health for a number of reasons. I had been surprised to uncover the mother’s eggs and embryo quality were so poor, despite her 34 years old,Inches stated Marjorie E. Dixon, M.D.C.M., F.R.C.S.(C), Medical Director initially Steps Fertility, Assistant Professor of Reproductive Endocrinology and Infertility in the College of Toronto, and also the patient’s reproductive endocrinologist. “Based on my small assessment of considerably reduced embryo quality inside a unsuccessful In vitro fertilization treatments cycle and many additional factors adding to her infertility, she’d couple of options. After I discovered the AUGMENT treatment, I had been excited to provide this couple a brand new chance to obtain their own biological child.”
“We were the very first clinic to give the AUGMENT treatment in Canada, and I’ve come across firsthand the positive impact it’s on pregnancy rates, specifically in women with poor prognoses,” stated Robert F. Casper, M.D., F.R.C.S.(C), Senior Investigator, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, and Medical Director of TCART Fertility Partners, where this AUGMENT treatment procedure required place. “The success of In vitro fertilization treatments depends upon many factors however, most fertility experts agree that egg and embryo quality are key prognostic indicators. The AUGMENT treatment was created to deal with egg and embryo quality, and we’re very happy to continue supplying the AUGMENT treatment to women that need new options.”
1 in 6 couples worldwide has trouble conceiving a child naturally. In vitro fertilization treatments may be the standard infertility treatment however, it frequently fails. Many physicians think that poor egg health accounts for almost all female-related infertility.
“Our mission at OvaScience would be to bring new fertility treatments to women with the aim of helping them build their own families,Inches stated Michelle Dipp, M.D., Ph.D., Ceo of OvaScience. “We expect to getting the AUGMENT treatment to more women all over the world in addition to future treatments from your egg precursor cell technology.”
Concerning the AUGMENTSM Treatment
The AUGMENT treatment methods are the very first fertility treatment open to patients according to OvaScience’s proprietary egg precursor (EggPCSM) cell technology. The AUGMENT treatment is made to improve the healthiness of a woman’s existing eggs, and boost the In vitro fertilization treatments procedure. The AUGMENT treatment uses energy-producing mitochondria from the woman’s own EggPC cells, that are immature egg cells based in the protective lining from the ovaries, to supplement the present mitochondria in her own eggs. Laser hair removal is made to improve egg health by growing the eggs’ levels of energy for embryo development. Egg health is really a main factor in In vitro fertilization treatments success. The AUGMENT treatment will come in select worldwide In vitro fertilization treatments clinics, and initial positive clinical encounters of pregnancies using the treatment happen to be reported. The AUGMENT treatment methods are unavailable within the U . s . States.
To learn more, check out www.augmenttreatment.com.
OvaScience (NASDAQ: OVAS) is really a global fertility company focused on improving treatments for ladies all over the world. OvaScience is finding, developing and commercializing new fertility treatments because we feel women deserve more options. Each OvaScience treatment is dependant on their proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found within the protective ovarian lining. The AUGMENTSM treatment, a fertility option particularly made to improve egg health, will come in certain In vitro fertilization treatments clinics in select worldwide regions outdoors from the U . s . States. OvaScience is developing the OvaPrimeSM treatment, that could increase a woman’s egg reserve, and also the OvaTureSM treatment, a possible next-generation In vitro fertilization treatments treatment that may help a lady produce healthy, youthful, fertilizable eggs without hormone injections. To learn more, check out www.ovascience.com and fasten around on Facebook.
This pr release includes forward-searching statements concerning the Company’s plans for that AUGMENT treatment and 2 fertility treatments in development. Actual results may vary materially from individuals shown by these forward-searching statements because of various key elements, including risks associated with: the chance that worldwide In vitro fertilization treatments clinics that people use may determine to not begin or continue supplying the AUGMENT strategy to commercial or any other reasons our expectation the AUGMENT treatment and OvaPrime treatment satisfy the needs of the type of products exempt from premarket review and approval under relevant rules in individuals countries where we’ve launched or intend to introduce the AUGMENT treatment and intend to introduce the OvaPrime treatment the commercial increase from the AUGMENT treatment, which we predict will be based upon the effective transition of ACE clinics to commercial operations, adding new ACE clinics, and also the is a result of ACE clinic experience because they become available the science underlying our treatment and coverings in development (such as the AUGMENT, OvaPrime and OvaTure treatments), that is misguided our capability to obtain regulatory approval where essential for our potential treatments our capability to develop our potential treatments, such as the OvaPrime and OvaTure treatments, around the timelines we predict, if our capability to commercialize the AUGMENT treatment and our potential treatments, such as the OvaPrime treatment, around the timelines we predict, if in addition to individuals risks more fully discussed within the “Risk Factors” portion of our most lately filed Questionnaire on Form 10-Q and/or Annual Set of Form 10-K. The forward-searching statements found in this pr release reflect our current views regarding future occasions. We anticipate that subsequent occasions and developments may cause our views to alter. However, basically we may want to update these forward-searching statements later on, we particularly disclaim any obligation to do this. These forward-searching statements shouldn’t be relied upon as representing our view by any date after the date hereof.
Theresa McNeely, 617-299-7356
EVP, Chief Communications Officer
Cara Mayfield, 617-714-9638
Director, Corporate Communications